Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02937961
Other study ID # ILBS-Septic Shock-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2017
Est. completion date March 1, 2019

Study information

Verified date January 2019
Source Institute of Liver and Biliary Sciences, India
Contact Dr Rakhi Maiwall, MD,DM
Phone 01146300000
Email rakhi_2011@yahoo.co.in
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Consecutive patients with cirrhosis and septic shock with AKI who give written informed consent will be included in this prospective trial. At baseline NT-Pro BNP, urine N-GAL will be done for all patients. A baseline serum blood sample (10 ml) and urine sample will be stored. Septic shock will be defined by the presence of two or more diagnostic criteria for the systemic inflammatory response syndrome, proven or suspected infection with hypotension non-responsive to adequate fluid resuscitation assessed by no evidence of stroke volume variation on flow track and need of a vasopressor to achieve a target mean arterial pressure (MAP) of ≥ 65 mm Hg. A record of CVP, IVC diameter and B-lines on ultrasound lung would also be done. Patients with age less than 18 years, severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, COPD) pregnancy, chronic kidney disease on hemodialysis, patients already meeting emergency criteria for immediate hemodialysis at the time of randomization as specified in the late group, patients transferred from other hospitals who have already been on hemodialysis before their arrival in the intensive care unit, extremely moribund patients with an expected life expectancy of less than 24 hours, failure to give informed consent from family members.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date March 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with Cirrhosis with septic shock associated AKI (Acute Kidney Injury) stage 3 AKIN/KDIGO stage 2.

Exclusion Criteria:

- Patients with age less than 18 years

- Severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, Coronary Obstructive Pulmonary Disease)

- Pregnancy

- Chronic kidney disease on hemodialysis

- Patients with Hepatorenal Syndrome, post renal obstructive AKI, AKI due to suspected based on history,urinalysis and past clinical records-glomerulonephritis, interstitial nephritis or vasculitis

- Patients already meeting emergency criteria for immediate hemodialysis at the time of randomization as specified in the late group (serum potassium>6 meq/lt, metabolic acidosis ph<7.12, acute pulmonary edema, severe volume overload with hypoxemia non-responsive to diuretic treatment)

- Patients transferred from other hospitals who have already been on hemodialysis before their arrival in the intensive care unit

- Extremely moribund patients with an expected life expectancy of less than 24 hours

- Failure to give informed consent from family members.

- Hemodynamic instability requiring very high dose of vasopressors

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Early SLED
withing 6 to 12 hours
Late SLED
when absolute indications will meet

Locations

Country Name City State
India Institute of Liver and Biliary Sciences New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transplant free survival in both groups 28 days
Secondary Incidence of intradialytic hypotension in both groups 48 hours
Secondary Hemodynamic stability in both groups 48 hours
Secondary Dialysis efficiency as measured by Urea Reduction ratio in both groups 2 days
Secondary Achievement of target ultrafiltration goals in both groups 48 hours
Secondary Recovery in renal functions in both groups Recovery is defined as an increase in urine output to more than 400 ml/day 14 days
Secondary Duration of Intensive Care Unit stay in both groups 28 days
Secondary Duration of mechanical ventilation in both groups 28 days
Secondary Improvement in Sequential Organ Failure Assessment ( by 2 points) scores in both groups 28 days
Secondary Improvement in SOFA, Model for End stage Liver Disease ( by 2 points) scores 28 days
Secondary Improvement in Acute Physiology and Chronic Health Evaluation ( by 2 points) scores 28 days
Secondary Improvement in lactic acidosis and lactate clearance at 6 initiation of dialysis in both groups 6 hours
Secondary Improvement in lactic acidosis and lactate clearance at 24 hours after initiation of dialysis in both groups 12 hours
Secondary Improvement in lactic acidosis and lactate clearance at 24 hours after initiation of dialysis in both groups 24 hours
Secondary Death related with renal failure in both groups 7 day
Secondary Mortality due to renal failure related in both groups. 7 day